Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
More...
Linear Mode
